Search
Paclitaxel Treatment Options in Los Angeles, CA
A collection of 347 research studies where Paclitaxel is the interventional treatment. These studies are located in the Los Angeles, CA. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
145 - 156 of 347
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Terminated
This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: City of Hope, Duarte, California +6 locations
Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Active Not Recruiting
This trial is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: University of California, Los Angeles, Los Angeles, California +2 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Active Not Recruiting
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: John Muir Health Clinical Research Center, Concord, California +8 locations
Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
A Study of ABT-165 in Subjects With Solid Tumors
Completed
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B were completed and for Cohorts C and D are recruiting.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/13/2023
Locations: University of California, Los Angeles /ID# 141389, Los Angeles, California +2 locations
Conditions: Advanced Solid Tumors
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Completed
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Alta Bates Comprehensive Cancer Center /ID# 1128-0135, Berkeley, California +9 locations
Conditions: Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Completed
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +7 locations
Conditions: Carcinoma, Pancreatic Ductal
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Completed
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: USC - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Cancer
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Completed
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Cedars Sinai Medical Care Foundation, Los Angeles, California
Conditions: Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Terminated
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Site #171, Duarte, California +1 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Completed
The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California +1 locations
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Terminated
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Disney Family Cancer Center, Burbank, California +6 locations
Conditions: Platinum-resistant Ovarian Cancer
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Completed
The purpose of this study is to find out what effects, good or bad, the combination of standard chemotherapy agent paclitaxel with the investigational (experimental) drug afatinib that targets HER2, has on HER2-positive esophagogastric cancer that started to get bigger despite previous treatment with trastuzumab. The doctors will also study the tumor to understand why it grew while on trastuzumab treatment and to see the effects afatinib and paclitaxel has on the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: University of Southern California, Los Angeles, California
Conditions: Esophageal Cancer, Gastric Cancer
145 - 156 of 347